DSTYK Enhances Chemoresistance in Triple-Negative Breast Cancer Cells

Breast cancer, as the most prevalent cancer in women, is responsible for more than 15% of new cancer cases and about 6.9% of all cancer-related death in the US. A major cause of therapeutic failure in breast cancer is the development of resistance to chemotherapy, especially for triple-negative brea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogbu, Stella C., Rojas, Samuel, Weaver, John, Musich, Phillip R., Zhang, Jinyu, Yao, Zhi Q., Jiang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750327/
https://www.ncbi.nlm.nih.gov/pubmed/35011659
http://dx.doi.org/10.3390/cells11010097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750327/
https://www.ncbi.nlm.nih.gov/pubmed/35011659
http://dx.doi.org/10.3390/cells11010097

Ejemplares similares